Challenges facing liposome-based targeted delivery of antithrombotic drugs

Haemorrhage is a major risk factor associated with administration of thrombolytic protein drugs. In vivo stability with conventional parenteral administration also remains a concern due to the intrinsic nature of thrombolytic protein drugs. Liposome-based delivery systems have been applied to other drugs in order to reduce toxicity, increase site specific action and protect against protein denaturation, but does the same apply to thrombolytic protein drugs and to what extent? Can liposome-based thrombolytic preparations reap the full benefits of this delivery system?

In the review article entitled “Liposomes for targeted delivery of antithrombotic drugs” Elbayoumi & Torchilin review the major work to date on liposome-based delivery of antithrombotic drugs to vascular pathology sites and provide their own perspective on the future of the field.

Will genomic technologies change the landscape of toxicology research?

With so many drug failures due to toxicity concerns, the development of more effective approaches to toxicity testing is of utmost importance. In their recent review “Systems biology and functional genomics approaches for the identification of cellular responses to drug toxicity,” Rusyn and Hege Harrill put forward the view that systems toxicology ‘offers the promise of more accurate predictions of adverse health effects in humans.’ They conclude that ‘Translational research bridging rodent and human toxicity will be the key to the success of this field.’ What will the impact of such approaches be on current gold standard? How widely used will they become?

1. Click Here to Receive a Free Token to Download the Paper

and then

2. Click Here to Take You to the Paper